What is the association between TTR and outcomes in AF?
TTR (Time in Therapeutic Range) is a measure of the proportion of time a patient with AF spends in the therapeutic range for their anticoagulation therapy (usually INR 2-3). Studies have shown an association between higher TTR and lower risk of stroke, systemic embolism, and all-cause mortality in AF patients. Higher TTR has also been linked with a lower risk of major bleeding and vascular death. However, the optimal TTR remains to be determined, as some studies have shown that a TTR of >80% does not necessarily provide additional benefit in terms of mortality or stroke prevention. Further research is needed to understand the optimal TTR and its association with outcomes in AF patients. 